EPO ELISA 11693417001

Erythropoietin (Epo) is a cytokine belonging to the hematopoietic cytokine superfamily. It has structural similarity to growth hormone and is encoded as a 193 amino acid polypeptide comprising of canonical leader sequence composed of 27 amino acid, and a carboxyl terminal arginine which is removed by posttranslational cleavage. Furthermore, Epo is produced in adult kidney and fetal liver and is involved in stimulating red blood cell production.
Specificity
The ELISA system detects both natural and recombinant human EPO from CHO cells. No cross-reaction with other serum components has been found.
Recognized epitope not known.
For research use only. Not for use in diagnostic procedures.
The EPO ELISA is designed for use in life science research studies as a method for the determination of EPO concentrations in plasma and serum; it is not intended for diagnostic procedures. The literature indicates that in certain forms of anemia, specifically in aplastic renal anemia, the regulation of EPO formation in the kidney appears to be intact. This may lead to an extremely high EPO concentration in serum of the respective individuals.
Exaggerated EPO levels, accompanied by a normal or even elevated hemoglobin concentration (and/or hematocrit values), have been found in a series of diseases (e.g., tumors of the kidney or liver, or in secondary forms of polycythemia). Polycythemia vera, however, is characterized by an abnormally increased red blood cell count  in tandem with a low EPO serum level. The EPO ELISA is intended to help increase scientific knowledge about these relationships.
Packaging
1 kit containing 10 components.
Unit Definition
Unit Conversion: The EPO concentration of unknown samples is calculated from a calibration curve. Each lot of standards (used for the calibration curve) is calibrated according to the 2. IRP WHO preparation (see lot-specific label). Conversion factor: 1 mlU/ml corresponds to 6.6 pg/ml. Conversion factor: 1 mU = 6.6 pg.
The normal range of a healthy human lies between 4 to 90 mIU/ml.
Preparation Note
Working solution: Solution 1 hEPO control serum (Bottle 1)
Reconstitute the lyophilizate in 500 µl double-distilled water for 10 min at 15 to 25 °C and mix thoroughly.
Warning: DO NOT VORTEX.
Result: A slightly milky solution.
Stability of Solution:

• 1 week at 2 to 8 °C
• 12 months at -15 to -25 °C

For Use in: step 1
Solution 2 Anti-hEPO-HRP (Bottle 2)
Reconstitute the lyophilizate in 500 µl double-distilled water for 10 min at 15 to 25 °C and mix thoroughly.
Warning: DO NOT VORTEX.
Result: A clear, colorless solution.
Stability of Solution:

• 12 months at 2 to 8 °C. Warning: do not freeze

For Use in: solution 9
Soluton 3a to 3f hEPO standard (Bottles 3a-3f)
Reconstitute the lyophilizate in 1 ml double-distilled water for 10 min at 15 to 25 °C and mix thoroughly.
Warning: DO NOT VORTEX.
Result: A clear, colorless solution.
Stability of Solution:

• 8 hours at 2 to 8 °C
• aliquot the rest to be used for subsequent standard curves and store at -15 to -25 °C

For Use in: step 1
Solution 4 Incubation buffer (Bottle 4)

• 100 ml
• Ready-to-use solution, clear, colorless

Stability of Solution: see kit label imprint
For Use in: solution 9
Solution 5 Sample buffer (Bottle 5)

• 100 ml
• Ready-to-use solution, clear or turbid, yellowish

Stability of Solution: see kit label imprint
For Use in: step 1
Solution 6 Washing buffer (Bottle 6)
Dissolve one tablet in 2 l of double-distilled water.
Result: A clear, colorless solution.
Stability of Solution: 12 months at 2 to 8 °C
For Use in: step 2
Solution 7 TMB substrate solution (Bottle 7)

• 15 ml
• Ready-to-use solution, clear colorless to slightly yellowish.

Stability of Solution: see kit label imprint
For Use in: step 3
Solution 8 TMB stop solution (Bottle 8)

• 7 ml
• Ready-to-use solution, clear, colorless

Stability of Solution: see kit label imprint
For Use in: step 4
Solution 9 Immunoreagent
For 100 wells (5 ml): Add 250 µl reconstituted anti-hEPO-HRP (solution 2) to 4.75 ml incubation buffer (solution 4), and mix well.
Stability of Solution: 8 hours at 2 to 8 °C. Warning: prepare shortly before use
For Use in: step 1
Storage conditions (working solution): Solution 1 hEPO control serum (bottle 1)
1 week at 2 to 8 °C
12 months at -15 to -25 °C
Solution 2 Anti-hEPO-HRP (bottle 2)
12 months at 2 to 8 °C
do not freeze!
Soluton 3 hEPO standard (bottles 3a-3f)
8 hours at 2 to 8 °C
aliquot the rest to be used for subsequent standard curves and store at -15 to -25 °C
Solution 4 Incubation buffer (bottle 4)
see kit label imprint
Solution 5 Sample buffer (bottle 5)
see kit label imprint
Solution 6 Washing buffer (bottle 6)
12 months at 2 to 8 °C
Solution 7 TMB substrate solution (bottle 7)
see kit label imprint
Solution 8 TMB stop solution (bottle 8)
see kit label imprint
Solution 9 Immuno-reagent
prepare shortly before use
8 hours at 2 to 8 °C
For life science research only. Not for use in diagnostic procedures.

usage	sufficient for 96 tests
Quality Level	100,
Торговая марка	Roche
storage temp.	2-8°C

pictograms	GHS05,GHS07,GHS09
signalword	Warning
hcodes	H290 - H315 - H317 - H319 - H411
pcodes	P261 - P264 - P273 - P280 - P333 + P313 - P391
RIDADR	UN 3316 9
WGK Germany	WGK 3
Flash Point F	Not applicable
Flash Point C	Not applicable